Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide

Leukemia Research

Volumn 31, Issue 9, 2007, Pages 1185-1189

  Zou, Ying S ^a   Fink, Stephanie R ^a   Stockero, Kimberly J ^a   Paternoster, Sarah F ^a   Smoley, Stephanie A ^a   Tun, Han W ^b   Reeder, Craig B ^c   Tefferi, Ayalew ^a   Dewald, Gordon W ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Acute leukemia; Deletion 5q; EGR1; Myelodysplasia

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; LENALIDOMIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; EGR1 PROTEIN, HUMAN; THALIDOMIDE; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME 5Q; CHROMOSOME ANALYSIS; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HEMATOLOGIC DISEASE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; PRIORITY JOURNAL; TREATMENT RESPONSE; ADULT; AGED; CHROMOSOME 5; DNA PROBE; GENETICS; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 5; CYTOGENETIC ANALYSIS; DNA PROBES; EARLY GROWTH RESPONSE PROTEIN 1; FEMALE; GENE DELETION; HEMATOLOGIC DISEASES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; THALIDOMIDE;

EID: 34249905898     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.10.011     Document Type: Article

References (18)

1. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Hematologic and cytogenetic (CTG) response to Lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study. 2005 ASCO Annual Meeting (2005)
2. List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., et al. Efficacy of Lenalidomide in myelodysplastic syndromes. N Engl J Med 352 6 (2005) 549-557
3. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. For the MDS-003 study investigators. Hematologic and cytogenetic response to Lenalidomide in myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355 (2006) 1456-1465
4. Giagounidis A.A., Germing U., and Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 12 1 (2006) 5-10
5. Dewald G.W., and Ketterling R.P. Conventional Cytogenetics and Molecular Cytogenetics in Hematological Malignancies. In: Hoffman R., Benz E., Shattil S., Furie B., Cohen H., Silberstein L., and McGlave P. (Eds). Hematology: Basic Principles and Practice 53 (2005), Churchill Livingston, Philadelphia 928-939
6. Heaney M.L., and Golde D.W. Myelodysplasia. N Engl J Med 340 (1999) 1649-1660
7. Dewald G.W., Davis M.P., Pierre R.V., O'Fallon J.R., and Hoagland H.C. Clinical characteristics and prognosis of 50 patients with a myeloproliferative syndrome and deletion of part of the long arm of chromosome 5. Blood 66 1 (1985) 189-197
8. Sole F., Espinet B., Sanz G., Cervera J., Calasanz M., Luno E., et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol 108 (2000) 346-356
9. Bernasconi P., Klersy C., Boni M., Cavigliano P.M., Calatroni S., Giardini I., et al. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia 19 8 (2005) 1424-1431
10. Giagounidis A.A., Germing U., Haase S., Hildebrandt B., Schlegelberger B., Schoch C., et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18 1 (2004) 113-119
11. Giagounidis A.A., Germing U., Strupp C., Hildebrandt B., Heinsch M., and Aul C. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of Lenalidomide in this patient subgroup. Ann Hematol 84 9 (2005) 569-571
12. Zhao N., Stoffel A., Wang P.W., Eisenbart J.D., Espinosa 3rd R., Larson R.A., et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci USA 94 13 (Jun 24 1997) 6948-6953
13. Mathew P., Tefferi A., Dewald G.W., Goldberg S.L., Su J., Hoagland H.C., et al. The 5q-syndrome: a single-institution study of 43 consecutive patients. Blood 81 4 (1993) 1040-1045
14. Horrigan S.K., Westbrook C.A., Kim H., Banerjee M., Stock W., and Larson R.A. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplatic syndrome identifies a minimal deletion intervel. Blood 88 (1996) 2665-2670
15. Pedersen-Bjergaard J., Andersen M., Christiansen D.H., and Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 99 6 (2002) 1909-1912
16. Bigoni R., Cuneo A., Milani R., Cavazzini F., Bardi A., Roberti M., et al. Multilineage involvement in the 5q-syndrome: a fluorescent in situ hybridization study on bone marrow smears. Haematologica 86 4 (2001) 375-381
17. Spurbeck J.L., Carlson R.O., Allen J.E., and Dewald G.W. Culturing and robotic harvesting of bone marrow, lymph nodes, peripheral blood, fibroblasts, and solid tumors with in situ techniques. Cancer Genet Cytogenet 32 1 (1988) 59-66
18. Ketterling R.P., Wyatt W.A., VanWier S.A., Law M., Hodnefield J.M., Hanson C.A., et al. Primary myelodysplastic syndrome with normal cytogenetics: utility of 'FISH panel testing' and M-FISH. Leuk Res 26 3 (2002) 235-240